NASDAQ: BCRX
Biocryst Pharmaceuticals Inc Stock Ownership - Who owns Biocryst Pharmaceuticals?

Insider buying vs selling

Have Biocryst Pharmaceuticals Inc insiders been buying or selling?

Buy
Sell
NameRoleDateSharesPriceValue
Jon P. StonehouseDirector2026-03-02305,995$8.64
$2.64MSell
Jon P. StonehouseDirector2026-03-02305,995$3.22
$985.30kBuy
Amy E. McKeeDirector2026-02-27642$8.75
$5.62kBuy
Jon P. StonehouseDirector2026-02-27421$8.75
$3.68kBuy
Steven FrankDirector2026-02-271,285$8.75
$11.24kBuy
Jill C. MilneDirector2026-02-27528$8.75
$4.62kBuy
Vincent MilanoDirector2026-02-27848$8.75
$7.42kBuy
Charles K. GayerPresident and CCO2025-12-2214,142$3.22
$45.54kBuy
Charles K. GayerPresident and CCO2025-12-2250,000$5.51
$275.50kBuy
Alane P. BarnesChief Legal Officer2025-12-2221,773$7.65
$166.56kSell

1 of 4

BCRX insiders have sold more... subscribe to Premium to read more.
Net Insider Buy/Sell (L12M) Ownership

Be the first to know when BCRX insiders and whales buy or sell their stock.

BCRX Shareholders

What type of owners hold Biocryst Pharmaceuticals Inc stock?

Institutional
Insider
Retail
NameHoldSharesValueType
Vanguard Group Inc8.88%22,273,375$183.09MInstitution
Baker Bros Advisors LP8.59%21,543,334$177.09MInsider
Blackrock Inc8.43%21,137,791$173.75MInstitution
Ra Capital Management LP6.31%15,827,186$130.10MInstitution
Deerfield Management Company LP5.72%14,341,000$117.88MInstitution
State Street Corp4.42%11,073,211$91.02MInstitution
Kynam Capital Management LP3.73%9,366,526$76.99MInstitution
Janus Henderson Group PLC2.95%7,404,386$60.86MInstitution
Ubs Group Ag2.10%5,263,914$43.27MInstitution
Geode Capital Management LLC2.02%5,053,786$41.54MInstitution

1 of 3

BCRX vs Biotech Stocks

TickerInst. %Insider %Net Insider (L12M)Net Insider (L3M)
BCRX83.18%15.21%Net SellingNet Selling
RARE85.42%14.58%Net SellingNet Selling
SNDX91.46%8.54%Net SellingNet Selling
GLPG47.64%0.00%
ZLAB2.62%1.77%Net BuyingNet Buying

Biocryst Pharmaceuticals Stock Ownership FAQ

Who owns Biocryst Pharmaceuticals?

Biocryst Pharmaceuticals (NASDAQ: BCRX) is owned by 83.18% institutional shareholders, 15.21% Biocryst Pharmaceuticals insiders, and 1.60% retail investors. Baker Bros Advisors LP is the largest individual Biocryst Pharmaceuticals shareholder, owning 21.54M shares representing 8.59% of the company. Baker Bros Advisors LP's Biocryst Pharmaceuticals shares are currently valued at $177.09M.

If you're new to stock investing, here's how to buy Biocryst Pharmaceuticals stock.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.